Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 4/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15193782 | 1.00 | ALDH1A1 (0.33) | ALDH1A1TSHRMAPK1MEN1KMT2A | |
| SCHEMBL17094524 | 1.00 | ALDH1A1 (0.33) | ALDH1A1TSHRMAPK1MEN1KMT2A | |
| SCHEMBL22204441 | 0.84 | ALDH1A1 (0.35) | ALDH1A1TSHRMAPK1TDP1 | |
| SCHEMBL17475524 | 0.82 | LMNA (0.33) | TSHRMEN1KMT2AHTTL3MBTL1 | |
| SCHEMBL22204431 | 0.82 | — | — | |
| SCHEMBL854782 | 0.81 | ALDH1A1 (0.31) | ALDH1A1 | |
| SCHEMBL5722071 | 0.80 | — | — | |
| SCHEMBL2767957 | 0.77 | SSTR4 (0.35) | — | |
| SCHEMBL1633115 | 0.77 | SSTR4 (0.35) | — | |
| SCHEMBL3102536 | 0.77 | SSTR4 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1328509-B1 | METHODS OF PRODUCING OXAZOLIDINONE COMPOUNDS | PHARMACIA & UPJOHN CO LLC (US) | 2006-03-22 | — | — | EP | claimed |
| US-20150266867-A1 | MONOBACTAM ORGANIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | NOVARTIS AG (CH) | 2015-09-24 | — | — | US | disclosed |
| CN-102260252-A | Novel oxazolidinone used for treating bacterial infection | — | 2011-11-30 | — | — | CN | disclosed |
| CN-101993448-A | Anti-mycobacteria oxazolidinones used for treating infectious disease | SHANGHAI CUMENCOR MEDICAL TECHNOLOGY CO LTD | 2011-03-30 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150266867-A1 | MONOBACTAM ORGANIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | MGAM, MGAM2, BPGM | ALDH1A1 431/4885TSHR 4851/4885MAPK1 3553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.